CIK 0000879407 · Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460408024
- Phone
- 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,186,600
- in 2 filings
Net −$1,186,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-11 | Vakiener Victoria Director | Sale 10b5-1 | −3,620 | $37.87 | $137K | 33,101 |
| 2024-01-11 | Vakiener Victoria Director | Sale 10b5-1 | −1,100 | $38.84 | $43K | 32,001 |
| 2024-01-05 | Oliver Tracie Chief Commercial Officer | Sale 10b5-1 | −74 | $33.89 | $3K | 136,501 |
| 2024-01-05 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −1,400 | $34.04 | $48K | 455,304 |
| 2024-01-05 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −5,800 | $34.97 | $203K | 449,504 |
| 2024-01-05 | Myszkowski Kenneth Allen Chief Financial Officer | Sale 10b5-1 | −8,904 | $35.65 | $317K | 440,600 |
| 2024-01-05 | San Martin Javier Chief Medical Officer | Sale 10b5-1 | −800 | $34.11 | $27K | 206,000 |
| 2024-01-05 | San Martin Javier Chief Medical Officer | Sale 10b5-1 | −3,100 | $35.03 | $109K | 202,900 |
| 2024-01-05 | San Martin Javier Chief Medical Officer | Sale 10b5-1 | −4,403 | $35.64 | $157K | 198,497 |
| 2024-01-05 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −1,800 | $34.00 | $61K | 249,134 |
| 2024-01-05 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −8,000 | $34.94 | $280K | 241,134 |
| 2024-01-05 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −12,343 | $35.65 | $440K | 228,791 |
| 2024-01-05 | Hamilton James C Chief Discovery/Trans Medicine | Sale 10b5-1 | −10,000 | $35.00 | $350K | 218,791 |
| 2024-01-05 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −1,900 | $33.99 | $65K | 485,326 |
| 2024-01-05 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −8,200 | $34.99 | $287K | 477,126 |
| 2024-01-05 | O'Brien Patrick COO and General Counsel | Sale 10b5-1 | −12,741 | $35.65 | $454K | 464,385 |
| 2024-01-04 | Oliver Tracie Chief Commercial Officer | Grant or award 10b5-1 | +75,000 | 136,575 | ||
| 2024-01-04 | Myszkowski Kenneth Allen Chief Financial Officer | Grant or award 10b5-1 | +75,000 | 456,704 | ||
| 2024-01-04 | San Martin Javier Chief Medical Officer | Grant or award 10b5-1 | +75,000 | 206,800 | ||
| 2024-01-04 | Hamilton James C Chief Discovery/Trans Medicine | Grant or award 10b5-1 | +75,000 | 250,934 |
Page 9 of 38 · 752 trades